News from NKTR, BMY and MRK. See Also: Biotechs’ Bizarre Performances in Early Trading Hours Today

News from Nektar
Nektar Therapeutics (NKTR) announced that new data from patients with metastatic triple-negative breast cancer, who were enrolled in the PIVOT-02 study, will be presented at the upcoming 5th CRI-CIMT-EATI-AACR Cancer Immunotherapy Conference being held from September 25 to September 28, 2019 in Paris, France.

The PIVOT-02 study is evaluating NKTR-214 . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.